MedTrace Logo

Efficacy of Ivermectin in Outpatients With Non-severe COVID-19

NCT04834115 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2021-04-06

No results posted yet for this study

Summary

This is a randomized controlled trial to evaluate the efficacy of ivermectin in reducing the risk of progression to severe disease and hospitalizations in COVID-19 patients.

Conditions

  • Covid19
  • Coronavirus Infection

Interventions

DRUG

Ivermectin Tablets

Oral ivermectin at a one time dose

OTHER

Placebo

Oral placebo at a one time dose

Sponsors & Collaborators

  • Consejo Nacional de Ciencias y Tecnologia, Paraguay

    collaborator UNKNOWN

  • Ministerio de Salud Pública y Bienestar Social, Paraguay

    collaborator UNKNOWN

  • Centro de información y recursos para el desarrollo, Paraguay

    collaborator UNKNOWN

  • Centro para el Desarrollo de la Investigación Científica, CEDIC, Paraguay

    collaborator UNKNOWN

  • Instituto Desarrollo, Paraguay

    collaborator UNKNOWN

  • Universidad Nacional de Asunción

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-17
Primary Completion
2021-04-30
Completion
2021-05-30

Countries

  • Paraguay

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04834115 on ClinicalTrials.gov